Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 160
- Registration Number
- NCT06409936
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 571
- Registration Number
- NCT05456191
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Boulder, Colorado, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
- Conditions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1484
- Registration Number
- NCT05286528
- Locations
- 🇭🇺
Pfizer, Budapest, Hungary
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT05185947
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 404
- Registration Number
- NCT04971226
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Texas Oncology Austin, Dallas, Texas, United States
🇺🇸Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States
Asciminib Roll-over Study
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT04877522
- Locations
- 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT04835584
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria Mater Domini, Catanzaro, Italy
🇮🇹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 51
- Registration Number
- NCT04838041
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 200
- Registration Number
- NCT04681820
- Locations
- 🇨🇳
Weiming Li, Wuhan, Hubei, China
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT04578847
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.